Repatha demonstrated a statistically significant 15% reduction in the risk of the primary composite endpoint.

Amgen announced that the Food and Drug Administration (FDA) has approved Repatha (evolocumab) for the prevention of heart attacks, strokes, and coronary revascularizations in adults with established cardiovascular disease.

Related Articles

Repatha is available as a 140mg/mL strength prefilled syringe or SureClick autoinjector for subcutaneous (SC) injection as well as a 420mg/3.5mL strength Repatha Pushtronex system, an on-body infusor with prefilled cartridge.